TransCode Therapeutics, Inc. filings document a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under RNAZ. Its regulatory record covers securities registration statements, material definitive agreements, unregistered equity issuances, preferred-stock rights, contingent value rights, and amendments to governing documents.
Current reports also furnish Regulation FD disclosures tied to clinical and preclinical oncology research, including TTX-MC138, RIG-I immunotherapy work, and FDA-related trial communications. Other filings address annual-report timing, emerging-growth-company status, shareholder-vote materials, capital-structure arrangements and formal disclosures associated with developing RNA and immuno-oncology therapeutics for advanced cancers.
TransCode Therapeutics, Inc. Schedule 13G/A filed by Anson-related parties reports collective beneficial ownership of 27,125 shares of TransCode common stock, representing 0.1% of the outstanding class when including shares underlying warrants. The reporting group includes Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and principals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the 27,125 shares and no sole voting or dispositive power reported. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control of the issuer.
TransCode Therapeutics, Inc. is the subject of a Schedule 13G reporting that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC together beneficially hold 49,018 shares, representing 5.9% of the outstanding common stock. The filing shows no sole voting or dispositive power and records shared voting and shared dispositive power for the reported shares, indicating the position is held collectively rather than controlled by a single entity.
The filing includes a joint filing agreement and an exhibit identifying the subsidiary that acquired the securities, and it contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.